← back to search

Changjun He

Harbin Medical University · CN
Area of research
Cancer Research · Molecular Biology
Research interest
Research focused on Cancer research and Sorafenib, with related work in Protein kinase B, Downregulation and upregulation, microRNA. Notable publications include 'MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway', 'LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells', and 'Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells'.
h-index
citations
844
works
16
NIH funding
primary concept
email

Recent publications

Sevoflurane Attenuates Proliferative and Migratory Activity of Lung Cancer Cells via Mediating the MicroRNA-100-3p/Sterol O-Acyltransferase 1 Axis
The Chinese Journal of Physiology 2023cited by 4position: lastdoi
PIGF and Flt-1 on the surface of macrophages induces the production of TGF-β1 by polarized tumor-associated macrophages to promote lung cancer angiogenesis
European Journal of Pharmacology 2021cited by 26position: lastdoi
Correction to: LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells
Journal of Experimental & Clinical Cancer Research 2021cited by 8position: middledoi
LncRNA TTN-AS1 promotes the progression of cholangiocarcinoma via the miR-320a/neuropilin-1 axis
Cell Death and Disease 2020cited by 55position: middledoi
Prediction of Pleural Invasion in Challenging Non-Small-Cell Lung Cancer Patients Using Serum and Imaging Markers
Disease Markers 2020cited by 11position: middledoi
LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells
Journal of Experimental & Clinical Cancer Research 2019cited by 206position: middledoi
Runt-related transcription factor 1 contributes to lung cancer development by binding to tartrate-resistant acid phosphatase 5
Cell Cycle 2019cited by 19position: firstdoi
Placental Growth Factor Mediates Crosstalk Between Lung Cancer Cells and Tumor-Associated Macrophages in Controlling Cancer Vascularization and Growth
Cellular Physiology and Biochemistry 2018cited by 18position: firstdoi
MicroRNA-138 Inhibits Cell Growth, Invasion, and EMT of Non-Small Cell Lung Cancer via SOX4/p53 Feedback Loop
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2017cited by 32position: middledoi
Musashi1 Promotes Non-Small Cell Lung Carcinoma Malignancy and Chemoresistance via Activating the Akt Signaling Pathway
Cellular Physiology and Biochemistry 2017cited by 29position: middledoi
Huge heterogeneity of patient characteristics, treatment patterns, hospital costs exists in non-small cell lung cancer surgeries among different centers of China: A study of 5060 patients based on the Chinese national NSCLC outcome registry.
Journal of Clinical Oncology 2016cited by 0position: middledoi
Clinical implications of transforming growth factor-beta–induced gene-h3 protein expression in lung cancer
OncoTargets and Therapy 2016cited by 0position: middledoi
MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway
Oncotarget 2015cited by 215position: firstdoi
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells
Cellular Signalling 2014cited by 138position: middledoi
Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation
Tumor Biology 2014cited by 47position: middledoi
Hydrogen Sulfide Protects Cardiomyocytes from Myocardial Ischemia-Reperfusion Injury by Enhancing Phosphorylation of Apoptosis Repressor with Caspase Recruitment Domain
The Tohoku Journal of Experimental Medicine 2012cited by 36position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Xueying Sun · Medical College of Wisconsin7 papers (2012–2021)Bo Zhai · Zhejiang Chinese Medical University6 papers (2014–2021)Hongchi Jiang · Nanjing University of Chinese Medicine6 papers (2012–2021)Xian Jiang · Sichuan University5 papers (2014–2021)Shidong Xu · Harbin Medical University5 papers (2017–2023)Xianglong Kong · Harbin Medical University4 papers (2019–2023)Gang Tan · Nanchang University4 papers (2012–2021)Kaibin Zhu · Harbin Medical University4 papers (2017–2020)Xue Bai · Hainan University3 papers (2016–2019)Xuesong Dong · Harbin Medical University3 papers (2015–2021)Jianlong Bu · Harbin Medical University3 papers (2017–2023)Bicheng Fu · Harbin Medical University3 papers (2019–2023)Ziyi Li · Guangxi University3 papers (2019–2021)Jing Feng · McGill University Health Centre2 papers (2019–2021)Jinfeng Ning · Harbin Medical University2 papers (2017–2018)Shangha Pan · Ministry of Education of the People's Republic of China2 papers (2012–2014)Lixin Ma · Indiana University School of Medicine2 papers (2014–2014)Yaoguo Lang · Jiangsu University2 papers (2018–2020)Boxiong Ni · Harbin Medical University2 papers (2021–2023)Shidong Xu · Harbin Medical University2 papers (2016–2020)